Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor modulators

Результат исследований: Научные публикации в периодических изданияхОбзорная статья

31 Цитирования (Scopus)

Выдержка

© 2014 Elsevier Masson SAS. 2-Imidazolines are well known as pharmacophores for various isoforms of adrenergic (α) and imidazoline (I) receptors. The biological activities exerted through the modulation of these targets, mostly in the central nervous system, have found utility in the development of many drug candidates - and even marketed drugs - for hypertension, diabetes and various CNS disorders. However, there is a growing evidence for the general privileged character of the 2-imidazoline scaffold, considering the documented success in the development of numerous biologically active compounds acting outside of the α/I receptor domain. In this review, we provide an overview of these, less traditional areas of medicinal applications of 2-imidazolines.
Язык оригиналаанглийский
Страницы (с-по)525-537
ЖурналEuropean Journal of Medicinal Chemistry
Том97
DOI
СостояниеОпубликовано - 2015

Отпечаток

Imidazoline Receptors
Scaffolds
Adrenergic Agents
Adrenergic Receptors
Modulators
Imidazolines
Neurology
Medical problems
Bioactivity
Pharmaceutical Preparations
Protein Isoforms
Central Nervous System
Modulation
Hypertension
2-imidazoline

Цитировать

@article{4470e0c7e9824289ad66ae7da467c51f,
title = "Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor modulators",
abstract = "{\circledC} 2014 Elsevier Masson SAS. 2-Imidazolines are well known as pharmacophores for various isoforms of adrenergic (α) and imidazoline (I) receptors. The biological activities exerted through the modulation of these targets, mostly in the central nervous system, have found utility in the development of many drug candidates - and even marketed drugs - for hypertension, diabetes and various CNS disorders. However, there is a growing evidence for the general privileged character of the 2-imidazoline scaffold, considering the documented success in the development of numerous biologically active compounds acting outside of the α/I receptor domain. In this review, we provide an overview of these, less traditional areas of medicinal applications of 2-imidazolines.",
author = "M. Krasavin",
year = "2015",
doi = "10.1016/j.ejmech.2014.11.028",
language = "English",
volume = "97",
pages = "525--537",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier",

}

Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor modulators. / Krasavin, M.

В: European Journal of Medicinal Chemistry, Том 97, 2015, стр. 525-537.

Результат исследований: Научные публикации в периодических изданияхОбзорная статья

TY - JOUR

T1 - Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor modulators

AU - Krasavin, M.

PY - 2015

Y1 - 2015

N2 - © 2014 Elsevier Masson SAS. 2-Imidazolines are well known as pharmacophores for various isoforms of adrenergic (α) and imidazoline (I) receptors. The biological activities exerted through the modulation of these targets, mostly in the central nervous system, have found utility in the development of many drug candidates - and even marketed drugs - for hypertension, diabetes and various CNS disorders. However, there is a growing evidence for the general privileged character of the 2-imidazoline scaffold, considering the documented success in the development of numerous biologically active compounds acting outside of the α/I receptor domain. In this review, we provide an overview of these, less traditional areas of medicinal applications of 2-imidazolines.

AB - © 2014 Elsevier Masson SAS. 2-Imidazolines are well known as pharmacophores for various isoforms of adrenergic (α) and imidazoline (I) receptors. The biological activities exerted through the modulation of these targets, mostly in the central nervous system, have found utility in the development of many drug candidates - and even marketed drugs - for hypertension, diabetes and various CNS disorders. However, there is a growing evidence for the general privileged character of the 2-imidazoline scaffold, considering the documented success in the development of numerous biologically active compounds acting outside of the α/I receptor domain. In this review, we provide an overview of these, less traditional areas of medicinal applications of 2-imidazolines.

U2 - 10.1016/j.ejmech.2014.11.028

DO - 10.1016/j.ejmech.2014.11.028

M3 - Review article

VL - 97

SP - 525

EP - 537

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -